20609-24-9

Upstream product

• 217302-91-5 5-amino-2-propylpyridine 
• 20609-07-8 2-propyl-pyridine N-oxide 
• 108-24-7 acetic anhydride 
• 228862-38-2 5-methoxy-2-propylpyridine 
• 1121-78-4 5-Hydroxy-2-methylpyridine 
• 55270-47-8 5-methoxy-2-picoline 
• 4808-69-9 6-methyl-3-sulfonylpyridine 
• 90376-92-4 6-propyl-2,3-pyridinedicarboxylic acid 
• 856858-01-0 (6-propyl-[3]pyridyl)-carbamic acid ethyl ester 
• 118419-90-2 Ethyl 6-propylnicotinate 
• 847046-96-2 6-propylnicotinic acid 
• 217302-90-4 5-nitro-2-propylpyridine 
• 4548-45-2 2-chloro-5-nitropyridine 

Downstream Products

• 5457-27-2 trans-5-hydroxy-2-propylpiperidine 
• 217302-95-9 6-benzyloxy-2-(4-benzyloxyphenyl)-1-ethylindolizine 
• 217302-97-1 dimethyl 7-benzyloxy-3-(4-benzyloxyphenyl)-4-ethylpyrrolo[2,1,5-cd]indolizine-1,2-dicarboxylate 
• 217302-98-2 7-benzyloxy-3-(4-benzyloxyphenyl)-4-ethylpyrrolo[2,1,5-cd]indolizine-1,2-dicarboxylic acid 

Relevant academic research and scientific papers

Synthesis and estrogen receptor binding affinities of novel pyrrolo[2,1,5-cd]indolizine derivatives

A series of pyrrolo[2,1,5-cd]indolizine derivatives has been synthesized and evaluated as ligands for the estrogen receptor. Properly substituted mono- and di-hydroxy derivatives showed binding in the low nanomolar range in accordance with their structural resemblance to estrogen. (C) 2000 Elsevier Science Ltd.

Pyrrolo[2,1,5-cd]indolizine derivatives useful in the prevention or treatment of estrogen related diseases or syndromes

The present invention relates to therapeutically active compounds of formula I a method of preparing the same and to pharmaceutical compositions comprising the compounds. The novel compounds are useful in the prevention or treatment of estrogen related diseases or syndromes.